Overcoming Downstream Bottlenecks in the Upscaling Process

Over the past decade, the demand for biological therapeutics, particularly monoclonal antibodies, has increased markedly. With annual demands for therapeutic antibodies reaching several metric tons, batches >100 kg of protein are becoming more common1. Technological advancement in cell culture ha...

To read the full article and other articles in this issue, please register for a free account or log in.

We will not sell or give your information to a third party. See our Privacy Policy



Subscribe to our FREE newsletter

We will not sell or give your information to a third party. See our Privacy Policy